Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On February 5, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2026 that ended December 31, 2025 and provided a business update.</li><li>The company recently launched REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).</li><li>Sales of the drug are off to an encouraging start, with over 100 prescriptions filled since the end of November.</li></ul>

On February 5, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2026 that ended December 31, 2025 and provided a business update.The company recently launched REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).Sales of the drug are off to an encouraging start, with over 100 prescriptions filled since the end of November.

ARWR: Strong Start for REDEMPLO Commercialization 